Guggenheim analyst Michael Schmidt raised the firm’s price target on Kymera Therapeutics to $45 from $41 and keeps a Buy rating on the shares after the company reported Q4 results and a business update that was consistent with the company’s recent immunology R&D day. Following the report, the firm is updating estimates to reflect financial results, updated operating expense assumptions for quarterly trends and updated estimates for the pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KYMR:
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Kymera Therapeutics sees cash runway into 1H27
- Kymera Therapeutics reports Q4 EPS (25c), consensus (40c)
- Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
- Kymera Therapeutics initiated with a Peer Perform at Wolfe Research
